Mazor Robotics (MZOR) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Mazor Robotics (NASDAQ:MZOR) announced its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.09, Morningstar.com reports. Mazor Robotics had a negative net margin of 28.80% and a negative return on equity of 22.68%. The company had revenue of $19.15 million during the quarter, compared to analysts’ expectations of $19.00 million. During the same quarter in the prior year, the company earned ($0.07) EPS. Mazor Robotics’s revenue was up 36.4% compared to the same quarter last year.

Mazor Robotics (NASDAQ MZOR) traded down $2.09 during trading hours on Wednesday, reaching $59.21. 447,300 shares of the company’s stock traded hands, compared to its average volume of 577,090. The firm has a market cap of $1,590.00, a price-to-earnings ratio of -85.59 and a beta of 1.16. Mazor Robotics has a 12 month low of $21.55 and a 12 month high of $69.37.

A number of large investors have recently bought and sold shares of the business. Global X Management Co. LLC boosted its holdings in Mazor Robotics by 127.8% in the 4th quarter. Global X Management Co. LLC now owns 263,147 shares of the medical instruments supplier’s stock valued at $13,578,000 after purchasing an additional 147,611 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its holdings in Mazor Robotics by 3.0% in the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 238,647 shares of the medical instruments supplier’s stock valued at $11,782,000 after purchasing an additional 6,905 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its holdings in Mazor Robotics by 1.9% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 159,052 shares of the medical instruments supplier’s stock valued at $7,852,000 after purchasing an additional 2,983 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in Mazor Robotics in the 3rd quarter valued at about $6,371,000. Finally, Dorsey Wright & Associates boosted its holdings in Mazor Robotics by 37.0% in the 4th quarter. Dorsey Wright & Associates now owns 121,540 shares of the medical instruments supplier’s stock valued at $6,272,000 after purchasing an additional 32,828 shares during the last quarter. Institutional investors own 26.40% of the company’s stock.

Several analysts recently issued reports on MZOR shares. BidaskClub raised shares of Mazor Robotics from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Zacks Investment Research raised shares of Mazor Robotics from a “hold” rating to a “buy” rating and set a $74.00 price objective for the company in a research note on Friday, February 2nd. Barclays reaffirmed a “sell” rating and set a $36.00 price objective on shares of Mazor Robotics in a research note on Tuesday, January 9th. TheStreet raised shares of Mazor Robotics from a “d” rating to a “c-” rating in a research note on Wednesday, November 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research note on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $45.67.

ILLEGAL ACTIVITY WARNING: “Mazor Robotics (MZOR) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/mazor-robotics-mzor-announces-quarterly-earnings-results-beats-expectations-by-0-09-eps.html.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Earnings History for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply